CRYSTAL KIZARR: Open Payments
NPI 1053661181 · DUNCAN, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,519 in 63 payments from 28 companies in 2025. Trend: 2023 $1,126 · 2024 $1,163 · 2025 $1,519
Food & beverage: $1,321Education: $198
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 13 | $285 |
| Janssen Biotech, Inc. | 6 | $199 |
| Incyte Corporation | 3 | $146 |
| Merck Sharp & Dohme LLC | 7 | $136 |
| Alexion Pharmaceuticals, Inc. | 2 | $64 |
| GENZYME CORPORATION | 2 | $63 |
| PFIZER INC. | 2 | $51 |
| Lilly USA, LLC | 3 | $49 |
| AstraZeneca Pharmaceuticals LP | 2 | $46 |
| KYOWA KIRIN, INC. | 2 | $44 |
Products named: RYBREVANT, KISQALI, KEYTRUDA, LUTATHERA, ULTOMIRIS, SARCLISA, SCEMBLIX, VERZENIO.
Industry payments across OK — which companies pay providers there.
